Galapagos extends drug discovery collaboration with Amgen into 2010
Galapagos NV announced that its service division BioFocus DPI has extended its longstanding drug discovery collaboration with Amgen through 2009 and 2010. BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply small molecule compounds for use in Amgen's discovery programs. Under the terms of the extended agreement, Galapagos will receive €2.0 M ($2.55 M) in research fees per year for two years. Additionally, Galapagos is eligible to receive compensation in the form of access fees and success-based milestones.
The collaboration, which was initiated in 2003 and extended in 2006, involves the identification of new molecules against drug targets from various protein classes, including ion channels, GPCRs and kinases.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.